article · Open Forum Infectious Diseases
Rifampicin-resistant tuberculosis presents a severe public health concern in regions where the disease is endemic. An evaluation of clinical trial data from four CAPRISA studies investigated how educational attainment and broader social determinants influence treatment success. Researchers developed an exploratory Social Disadvantage Score incorporating education, employment status, and incarceration history. The analysis revealed that educational attainment alone was not significantly tied to poor treatment outcomes. However, individual factors such as prior imprisonment and unemployment substantially raised the risk of treatment failure. Crucially, the accumulation of multiple social vulnerabilities displayed a clear dose-response relationship, with individuals experiencing three distinct disadvantages facing a nearly sixfold rise in the hazard of unfavourable outcomes. These findings demonstrate that overlapping social hardships considerably hinder recovery, highlighting the necessity of targeted supportive interventions for high-risk patients undergoing treatment for drug-resistant tuberculosis.
Rifampicin-resistant tuberculosis is notoriously difficult to cure, and standard clinical interventions may prove insufficient if social barriers are ignored. By pinpointing how specific vulnerabilities like unemployment and imprisonment compound treatment failure, healthcare programmes can design better holistic care pathways. Addressing these structural factors alongside medical therapies could substantially improve patient recovery rates and curtail ongoing transmission across vulnerable communities.
The abstract outlines epidemiological research rather than a proprietary technology, but the exploratory scoring framework could inform digital health risk-stratification tools. Public health providers and software developers could adapt these indicators into clinical decision-support platforms to identify patients needing social support. However, this concept is early-stage research based on retrospective clinical trial data and requires further validation and operational testing before real-world use.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Background Rifampicin-resistant tuberculosis (RR-TB) remains a major public health challenge in TB-endemic regions. While social determinants of health, including socioeconomic status, affect infectious disease outcomes, their impact on RR-TB remains poorly understood. This study evaluated the relationship between educational attainment, social disadvantage, and RR-TB outcomes. Methods We conducted a retrospective cohort study using data from four CAPRISA RR-TB clinical trials. Social vulnerability was measured using an exploratory Social Disadvantage Score (SDS) that incorporated education, employment, and incarceration. We used a latent class analysis (LCA) to identify classes with shared social vulnerability indicators. Associations with treatment outcomes were assessed using separate Cox regression models, with the exploratory SDS, its component indicators, and derived latent classes as predictors. Results Education was not independently associated with unfavourable treatment outcomes (aHR=1.39, 95% CI: 0.96–1.99, p=0.077), whereas a history of incarceration doubled the hazard (aHR=2.05, 95% CI: 1.33–3.16, p<0.001). Restricting subsequent models to the sub-cohort with collected employment data, unemployment increased the hazard of unfavourable outcomes (aHR=1.84, 95% CI: 1.20–2.82, p=0.005). Using the same sub-cohort, increasing cumulative social disadvantage showed a strong dose–response relationship, with a fivefold higher hazard for three disadvantages (aHR=5.85, 95% CI: 2.73–12.56, p < 0.001). LCA revealed that Class 2 (moderate socioeconomic advantage) had a significantly higher hazard of unfavourable outcomes (aHR=1.82, 95% CI: 1.19–2.79, p=0.006). Conclusion Cumulative social risk score was associated with unfavourable RR-TB outcomes. These findings support further evaluation of targeted support for disadvantaged populations to enhance RR-TB treatment success.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/ofid/ofag531
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
